Ultralife (ULBI) Q1 2026: Backlog Surges 21% as New Product Pipeline Sets Up Recovery
Ultralife’s record $115 million backlog and $12 million in new product orders signal a strategic pivot toward future growth despite Q1 operational setbacks. Margin compression and plant disruptions weighed on profitability, but leadership doubled down on vertical integration and brand consolidation to unlock leverage. Investors should watch execution on ramping new programs and margin recovery as the year unfolds.
Summary
- Backlog Expansion Drives Visibility: Historic backlog and new product orders underpin management’s growth thesis.
- Margin Pressure from Disruption: Weather, plant shutdowns, and one-time costs hit gross margin and profitability.
- Execution on New Programs Critical: Ramp of wearable battery, AI compute, and vertical integration will define 2026 trajectory.
Business Overview
Ultralife Corporation (ULBI) designs and manufactures portable power solutions and communication systems for commercial, government, defense, medical, and industrial customers. The business operates two main segments: battery and energy products, which comprises the bulk of revenue, and communication systems, focused on RF (radio frequency) and ruggedized computing solutions. Revenue is generated from both commercial and government contracts, with a growing portfolio of bespoke and OEM (original equipment manufacturer) projects.
Performance Analysis
Q1 2026 results reflected a confluence of operational headwinds and strategic investment. Revenue declined year over year, with battery and energy product sales down due to lower oil and gas demand and a tough comparison from a large defense order last year. Medical sales provided a modest offset, rising nearly 6%. The communication systems segment suffered a 26% drop, largely from order timing and slow baseline demand, underscoring the urgency of new product launches.
Gross margin compressed by 380 basis points, driven by lost production days from weather, plant reorganization, and ERP integration, as well as higher energy and tariff costs. Operating expenses increased over 10%, inflated by one-time consulting and litigation fees, and stepped-up investment in new product development and vertical integration. The company posted a small operating loss, with adjusted EBITDA margin falling to 6.8% of sales. Despite these near-term pressures, the record $115.1 million backlog (up 21%)—including $12 million from products launched in the past year—provides a foundation for recovery as new programs ramp.
- Order Timing and Disruption: Shipment delays, weather, and plant shutdowns drove lost production days and weighed on both revenue and margin.
- Segment Divergence: Battery and energy remains the anchor, but communication systems’ underperformance highlights strategic risk and upside.
- Cost Structure in Flux: One-off consulting, litigation, and inventory realignment costs are expected to taper, but margin recovery depends on execution.
Management’s willingness to invest ahead of revenue in labor, leadership, and new product development is a calculated bet on backlog conversion and margin recovery in the coming quarters.
Executive Commentary
"We have a growing backlog and product portfolio due to new product releases that we need to support this year, so we have added and trained direct labor resources in Arranum and Newark facilities to staff lines for the increased demand expected in 2026. This expense comes pre-revenue is critical given the nature of our products to ensure product quality."
Mike Manna, President and CEO
"Our total backlog exiting the first quarter was 115.1 million, the highest level in the company's history... The backlog remains diverse in nature across our commercial and government defense customer base, and the replenishment rate remains high, representing 61% of trailing 12-month sales."
Phil Fain, Chief Financial Officer
Strategic Positioning
1. Backlog Conversion and New Product Ramp
With $115 million in backlog—$12 million from recent launches—Ultralife’s immediate focus is on converting orders into revenue, particularly in high-potential areas like conformal wearable batteries and AI compute solutions. Timely execution is essential given the pre-revenue costs already incurred for labor and training.
2. Margin Recovery and Operational Efficiency
Margin improvement is a top priority, with new plant leadership and corrective actions targeting scrap and inefficiency at Newark and other facilities. Management expects these changes to begin impacting results mid-year, as legacy issues are worked through and lean initiatives scale.
3. Vertical Integration and Brand Consolidation
The integration of Electrochem cells and transition to the Ultralife master brand are designed to unlock cost leverage, broaden the addressable market, and simplify customer messaging. The telemetry power systems sub-division is expected to double internal cell usage as customer qualifications complete.
4. Communication Systems Turnaround
Despite another weak quarter, management is doubling down on new product development, targeting military vehicle adapters, ruggedized computing, and tactical network hubs. Success in winning new baseline and recurring revenue is critical to stabilizing this segment.
5. OEM and Medical Pipeline Expansion
Multiple OEM and medical projects are advancing, including new battery packs for medical devices and thin cell technology for wearables. These projects, while long-cycle, diversify the revenue base and support Ultralife’s positioning in higher-value, stickier markets.
Key Considerations
This quarter’s results reflect a business in transition, balancing near-term disruption with long-term growth investments. The strategic context is shaped by backlog-driven visibility, execution risk on new programs, and the need for margin restoration.
Key Considerations:
- Backlog Quality and Timing: Conversion of record backlog is central to the 2026 recovery narrative, but depends on customer launch schedules and internal execution.
- Margin Inflection Watch: Gross margin improvement hinges on operational fixes and volume leverage, with mid-year as a key checkpoint.
- Communication Systems Risk: Sustained underperformance could drag on results unless new products and baseline revenue materialize.
- Vertical Integration Upside: Success in doubling internal cell usage can structurally lower costs and enhance differentiation.
- One-Time Cost Normalization: Consulting, litigation, and ERP transition costs are expected to abate, but investors should monitor for further non-recurring items.
Risks
Execution risk looms large as Ultralife works to ramp new products and restore margins amid a still-volatile operating environment. Delays in customer launches, further plant disruptions, or failure to stabilize the communication systems segment could prolong margin pressure. Tariff and energy cost volatility, as well as reliance on government and OEM procurement cycles, add to the uncertainty. Management’s confidence is clear, but the path to normalized profitability requires sustained operational discipline.
Forward Outlook
For Q2 and the remainder of 2026, Ultralife leadership emphasized:
- Backlog conversion, with $8 million in conformal wearable battery orders expected to ship in 2026
- Ramp of new commercial and military programs, including tactical network hubs and advanced amplifiers
For full-year 2026, management did not provide explicit financial guidance but reiterated:
- Focus on gross margin recovery, especially at Newark
- Doubling internal cell usage as vertical integration scales
Management highlighted several factors that will drive results: timing of customer launches, operational execution on margin initiatives, and successful ramp of new products in both segments.
- Customer program schedules and qualification cycles remain gating factors
- Margin improvement expected to materialize in the second half as operational fixes take hold
Takeaways
Ultralife’s Q1 marks a transitional period, with short-term pain from disruption offset by a record backlog and new product launches that could reshape the company’s trajectory if executed well.
- Backlog-Driven Visibility: The $115 million backlog and diversified pipeline provide a cushion and opportunity for revenue acceleration, but require flawless execution to translate into margin and earnings improvement.
- Margin Rebuild in Focus: Operational and one-time cost headwinds are expected to fade, but investors should look for clear evidence of gross margin inflection by mid-year.
- Program Ramp Will Define 2026: The pace of new product commercialization and stabilization of communication systems will determine whether Ultralife can deliver on its growth and profitability ambitions.
Conclusion
Ultralife’s Q1 results reflect a company in the midst of strategic repositioning, with backlog strength and new product momentum offsetting near-term operational and margin headwinds. Execution on backlog conversion and margin recovery is the critical watchpoint for investors through 2026.
Industry Read-Through
Ultralife’s experience this quarter highlights several themes for the portable power and defense electronics sector. Backlog visibility and new product launches are increasingly vital as procurement cycles lengthen and customer customization rises. Margin pressure from operational disruption, energy, and tariffs is a shared challenge, underscoring the importance of vertical integration and supply chain resilience. For peers, the ability to ramp new programs and restore margin leverage amid cost volatility will separate winners from laggards in the coming year. The slow rebound in government and defense communications spending also suggests that baseline revenue is increasingly dependent on innovation and new program wins, not legacy contracts.